Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 15/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 16/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553803 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL28763254 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL4002165 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL11531304 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL15903011 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL570688 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL4001414 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL6342298 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL22828775 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA | |
| SCHEMBL4002558 | 0.98 | CTRC (0.64) | CTRCPPARGPTGESALOX5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102573790-B | Implantable device for production of interleukin-1 receptor antagonist | 拜欧米特生物制剂有限责任公司 | 2017-03-22 | — | — | CN | claimed |
| CN-102755670-B | Preparation method of traceable biodegradable polymer bracket | LI WENTAO | 2014-04-09 | — | — | CN | claimed |
| US-20090215154-A1 | Method of preparing micro-and nanometric particles with labile Products | SIRROM PARTNERS, L.P. | 2009-08-27 | — | — | US | claimed |
| US-20090214655-A1 | Method and Device for Obtaining Micro and Nanometric Size Particles | SIRROM PARTNERS, L.P. | 2009-08-27 | — | — | US | claimed |
| EP-1951790-A2 | INITIATORS AND CROSSLINKABLE POLYMERIC MATERIALS | A Enterprises, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1880762-A2 | METHOD OF PREPARING MICRO- AND NANOMETRIC PARTICLES WITH LABILE PRODUCTS | Universidad de Sevilla (ES) | 2008-01-23 | — | — | EP | claimed |
| EP-1842584-A1 | METHOD AND DEVICE FOR OBTAINING MICRO AND NANOMETRIC SIZE PARTICLES | Universidad de Sevilla (ES) | 2007-10-10 | — | — | EP | claimed |
| WO-2007081396-A9 | INITIATORS AND CROSSLINKABLE POLYMERIC MATERIALS | ENTPR INC A (US) | 2007-09-07 | — | — | WO | claimed |
| WO-2007081396-A2 | INITIATORS AND CROSSLINKABLE POLYMERIC MATERIALS | A ENTERPRISES, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| US-20060052471-A1 | Initiators and crosslinkable polymeric materials | A ENTERPRISES, INC. | 2006-03-09 | — | — | US | claimed |
| US-6613358-B2 | Contacting an organic solvent with co-dissolved a biocompatible polymer and a hydrophobic ion pair complex of an amphiphilic material and pharmaceutical with a compressed antisolvent fluid | ENDO PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | claimed |
| US-12605423-B2 | Peptide inhibitors targeting methyltransfer mechanism of SARS-CoV-2 | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2026-04-21 | — | — | US | disclosed |
| US-12377191-B2 | Chondroinductive peptides and compositions and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250180544-A1 | ARTIFICIAL SERTOLI CELLS AND METHOD FOR THEIR PRODUCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-06-05 | — | — | US | disclosed |
| EP-4543313-A1 | SYSTEMS AND METHODS FOR TUNING ABSORPTION PATHWAYS IN BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20020054912-A1 | Microparticles | BOARD OF TRUSTEES OF UNIVERSITY OF LLINOIS | 2002-05-09 | — | — | US | disclosed |
| WO-2002013786-A2 | METHOD OF FORMING MICROPARTICLES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1054052-A2 | Stabilized hydrotreated and hydrodewaxed lubricant compositions | Ciba SC Holding AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| US-4073739-A | Toner powder for electrostatic images comprising epoxy resin | OCE-VAN DER GRINTEN, N.V. (NL) | 1978-02-14 | — | — | US | disclosed |
| US-3985559-A | Toner powder for electrostatic images | OCE-VAN DER GRINTEN N.V. (NL) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605423-B2 | Peptide inhibitors targeting methyltransfer mechanism of SARS-CoV-2 | METTL16, SARS1, RNMT | CTRC 4471/4885PPARG 4203/4885PTGES 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.